ACP
AGRX

Acuta Capital Partners’s Agile Therapeutics AGRX Stock Holding History

Acuta Capital Partners’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-71
Closed -$952K – 70
2015
Q3 		$952K Buy
71
+7
+11% +$124K 0.55% 45
2015
Q2 		$1.1M Buy
64
+24
+60% +$512K 0.68% 36
2015
Q1 		$750K Buy
+40
New +$701K 0.63% 38

Other funds holding AGRX

PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Acuta Capital Partners's AGRX Position: Q4 2015 in Review

Acuta Capital Partners sold out of Agile Therapeutics (AGRX) in Q4 2015, closing a stake of 71 shares — an estimated $952K sold.

Acuta Capital Partners first reported a position in AGRX in Q1 2015 and held it in 3 quarters. The position peaked at $1.1M in Q2 2015. 45 funds tracked by Wall St. Rank hold AGRX as of Q4 2015.

  • Acuta Capital Partners reported no remaining Agile Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Acuta Capital Partners sold 71 Agile Therapeutics shares in Q4 2015, an estimated $952K.
  • Acuta Capital Partners first reported a position in Agile Therapeutics in Q1 2015 and held it in 3 quarters.
  • Acuta Capital Partners's Agile Therapeutics position peaked at $1.1M in Q2 2015.
  • 45 funds tracked by Wall St. Rank held Agile Therapeutics as of Q4 2015.

Based on Acuta Capital Partners's 13F filing for Q4 2015, filed 12 Feb 2016.